Screener
NovoCure NVCR Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $193.4M+15.7% | $183.58M+15.6% | $174.06M+12.3% | $174.35M+8.1% | $167.2M+7.8% | ||
| $44.53M-0.4% | $41.11M-0.9% | $38.93M+1.1% | $42.16M+26.0% | $44.73M+26.5% | ||
| $148.87M+21.6% | $142.48M+21.4% | $135.13M+16.0% | $132.19M+3.4% | $122.48M+2.3% | ||
| 77%+3.7pp | 77.6%+3.7pp | 77.6%+2.5pp | 75.8%-3.4pp | 73.2%-3.9pp | ||
| $58.1M+7.5% | $51.45M-7.9% | $58.34M+8.5% | $60.91M+18.9% | $54.03M+4.1% | ||
| $53.3M-9.0% | $61.68M+8.1% | $58.36M+4.6% | $68.66M+1.9% | $58.55M-2.1% | ||
| $43.65M-5.0% | $39.91M-9.2% | $85.85M+91.8% | $43.02M-40.6% | $45.92M+14.5% | ||
| $155.04M-2.2% | $153.04M-2.4% | $202.55M+31.2% | $172.59M-9.7% | $158.5M+4.4% | ||
| -$6.17M+82.9% | -$10.56M+73.3% | -$67.42M-78.1% | -$40.39M+36.2% | -$36.02M-12.2% | ||
| -3.2%+18.4pp | -5.8%+19.1pp | -38.7%-14.3pp | -23.2%+16.1pp | -21.5%-0.9pp | ||
| -$1.71M-128% | -$1.89M-142% | -$1.84M-124% | $0-100% | $6M-42.9% | ||
| -$7.88M+73.8% | -$12.45M+64.4% | -$69.26M-129% | -$40.95M+25.8% | -$30.02M-39.1% | ||
| $2.56M-64.7% | $3.21M-37.9% | $1.88M-53.3% | -$16.46M-254% | $7.25M-19.3% | ||
| -$10.44M+72.0% | -$15.66M+61.0% | -$71.14M-107% | -$24.5M+62.8% | -$37.27M-21.9% | ||
| -5.4%+16.9pp | -8.5%+16.7pp | -40.9%-18.7pp | -14.1%+26.8pp | -22.3%-2.6pp | ||
| -$0.09+72.7% | -$0.13+63.9% | -$0.62-100% | -$0.22+63.9% | -$0.33-17.9% | ||
| -$1.76M+94.6% | -$6.26M+82.7% | -$63.3M-83.3% | -$36.18M+39.9% | -$32.36M-9.2% | ||
| -0.9%+18.4pp | -3.4%+19.3pp | -36.4%-14.1pp | -20.7%+16.6pp | -19.4%-0.2pp | ||
| -$6.17M+82.9% | -$10.56M+73.3% | -$67.42M-78.1% | -$40.39M+36.2% | -$36.02M-12.2% |
FAQ
- What is NovoCure's revenue?
- NovoCure (NVCR) generated $725.4M in revenue over the trailing twelve months, up 12.9% year over year.
- Is NovoCure profitable?
- NovoCure is not currently profitable: it reported a net loss of $121.7M over the trailing twelve months, a -16.8% net margin.
- What are NovoCure's profit margins?
- Gross margin is 77.0% and operating margin is -17.2%, with a -16.8% net margin.
- What is NovoCure's earnings per share?
- NovoCure's diluted EPS over the trailing twelve months is $-1.06.
- Where does NovoCure's income statement data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
